Would you change AR signaling inhibitor in a patient with high volume metastatic castration-sensitive prostate cancer who started darolutamide with initial plan for docetaxel but in whom chemotherapy was eventually deferred?

Topics: Genitourinary Cancers • Prostate Cancer • Medical Oncology

Would you switch to enzalutamide or apalutamide if not giving docetaxel given darolutamide data for mCSPC is only from ARASENS trial with docetaxel?

Answer from: Medical Oncologist at Academic Institution

The ARASENS trial showed a survival benefit for the combination of ADT with chemotherapy and Darolutamide in mHSPC. In a patient with high-volume disease who has been initiated on Darolutamide but in whom chemotherapy was planned but then deferred, I would continue with Darolutamide if the patient i...

Comments

Medical Oncologist at Huntsman Cancer Institute - University of Utah Health Care
Additionally, I will add that based on the premise...

Related Questions